Aprea Therapeutics (APRE) EBT (2022 - 2026)
Aprea Therapeutics (APRE) posted quarterly EBT of -$3.4 million for Q1 2026, up 16.04% year-over-year from -$3.0 million in Q1 2025, and up 94.18% quarter-over-quarter from -$59.0 million in Q4 2025.
Aprea Therapeutics (APRE) EBT (2022 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported EBT for 5 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 16.04% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$68.9 million (down 5.36% YoY), while the FY2025 annual figure was -$69.6 million, down 7.91% from the prior year.
- EBT climbed to -$3.4 million in Q1 2026 per APRE's latest filing, from -$59.0 million in the prior quarter.
- Across five years, EBT topped out at -$2.8 million in Q4 2022 and bottomed at -$98.5 million in Q2 2022.
- Historically, EBT has averaged -$19.2 million across 5 years, with a median of -$4.0 million in 2024.
- On a YoY basis, EBT climbed as much as 96.29% in 2023 and fell as far as 1808.28% in 2023.
- Aprea Therapeutics' EBT stood at -$2.8 million in 2022, then sank by 1808.28% to -$53.1 million in 2023, then dropped by 0.51% to -$53.4 million in 2024, then slipped by 10.49% to -$59.0 million in 2025, then surged by 94.18% to -$3.4 million in 2026.
- Business Quant data shows APRE's EBT at -$3.4 million in Q1 2026, -$59.0 million in Q4 2025, and -$3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 81.49 Mn |
| 10 | Aprea Therapeutics | 34.85 Mn | 34.85 Mn | - | -3.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.03 Mn |
| Mar 31, 2026 | -3.43 Mn |
| Dec 31, 2025 | -58.99 Mn |
| Sep 30, 2025 | -3.12 Mn |
| Jun 30, 2025 | -3.39 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Dec 31, 2024 | -53.39 Mn |
| Sep 30, 2024 | -4.10 Mn |
| Jun 30, 2024 | -3.85 Mn |
| Mar 31, 2024 | -3.15 Mn |
| Dec 31, 2023 | -53.12 Mn |
| Sep 30, 2023 | -3.52 Mn |
| Jun 30, 2023 | -3.65 Mn |
| Mar 31, 2023 | -4.62 Mn |
| Dec 31, 2022 | -2.78 Mn |
| Sep 30, 2022 | -4.19 Mn |
| Jun 30, 2022 | -98.53 Mn |